ALX Oncology Holdings Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 32.92 million compared to USD 16.27 million a year ago. Basic loss per share from continuing operations was USD 0.81 compared to USD 0.4 a year ago.
For the six months, net loss was USD 57.45 million compared to USD 30.46 million a year ago. Basic loss per share from continuing operations was USD 1.41 compared to USD 0.76 a year ago.